Skip to main content
. 2018 Nov 13;12:2413–2424. doi: 10.2147/PPA.S182563

Figure 4.

Figure 4

Change from baseline in number of days per month with acute medication use for migraine or headache. Changes at each month (A) and overall change (B) from baseline are shown.

Notes: Results are LS mean change ± SE from baseline. Significant within-group differences were noted in both the GMB dose groups at each month and overall, ^p<0.001.

Abbreviations: GMB, galcanezumab; SE, standard error; LS, least squares.